Literature DB >> 8627067

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

A K Bhattacharjee1, S M Opal, R Taylor, R Naso, M Semenuk, W D Zollinger, E E Moran, L Young, C Hammack, J C Sadoff, A S Cross.   

Abstract

Earlier studies showed that purified IgG from sera of rabbits immunized with a boiled Escherichia coli J5 (Rc chemotype) whole cell vaccine protected neutropenic rats against gram-negative bacterial sepsis. In the present study, de-O-acylated J5 lipopolysaccharide (J5 DLPS) as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (GBOMP) elicited anti-J5 LPS antibodies in rabbits. IgG prepared from immune rabbit sera protected neutropenic rats against lethal challenge with Pseudomonas aeruginosa 12:4:4 (Fisher Devlin immunotype 6). Sixteen of 26 rats treated with the postimmune serum IgG were protected compared with none of 20 rats treated with the control rabbit serum IgG (P < .001). In vitro binding studies showed binding of anti-J5 IgG to several gram-negative bacteria. These results indicate that a subunit vaccine made of J5 DLPS as a noncovalent complex with GBOMP may protect against gram-negative bacteremia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627067     DOI: 10.1093/infdis/173.5.1157

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

Review 3.  Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Authors:  S M Opal; R L Yu
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

4.  Top Down Tandem Mass Spectrometric Analysis of a Chemically Modified Rough-Type Lipopolysaccharide Vaccine Candidate.

Authors:  Benjamin L Oyler; Mohd M Khan; Donald F Smith; Erin M Harberts; David P A Kilgour; Robert K Ernst; Alan S Cross; David R Goodlett
Journal:  J Am Soc Mass Spectrom       Date:  2018-02-20       Impact factor: 3.109

5.  Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications.

Authors:  Mohamed El Khattabi; Hendrik Adams; Erik Heezius; Pim Hermans; Frank Detmers; Bram Maassen; Peter van der Ley; Jan Tommassen; Theo Verrips; Jord Stam
Journal:  Clin Vaccine Immunol       Date:  2006-08-23

6.  Cross-reactive polyclonal antibodies to the inner core of lipopolysaccharide from Neisseria meningitidis.

Authors:  Svein Rune Andersen; Terry Guthrie; Geoffrey R Guile; Jan Kolberg; Sam Hou; Lisa Hyland; Simon Y C Wong
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

7.  Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors.

Authors:  Wilbur H Chen; Subhendu Basu; Apurba K Bhattacharjee; Alan S Cross
Journal:  Innate Immun       Date:  2009-10-12       Impact factor: 2.680

8.  Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.

Authors:  Deborah R Leitner; Sandra Feichter; Kristina Schild-Prüfert; Gerald N Rechberger; Joachim Reidl; Stefan Schild
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

9.  Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide.

Authors:  Ji Eun Han; Seo Ri Wui; Kwang Sung Kim; Yang Je Cho; Wan Je Cho; Na Gyong Lee
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

Review 10.  Anti-endotoxin vaccines: back to the future.

Authors:  Alan S Cross
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.